Nantahala Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Nantahala Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20M	Buy	5,475,040 +2,425,000	+80%	+$14.8M	0.66%	42
2026 Q1	$23.4M	Sell	3,050,040 -1,243,306	-29%	-$11.5M	0.86%	30
2025 Q4	$48.6M	Sell	4,293,346 -377,438	-8%	-$3.84M	1.61%	12
2025 Q3	$43M	Buy	4,670,784 +382,485	+9%	+$2.77M	1.49%	14
2025 Q2	$29.5M	Sell	4,288,299 -534,394	-11%	-$2.86M	1.16%	15
2025 Q1	$13.9M	Buy	4,822,693 +42,985	+0.9%	+$158K	0.55%	30
2024 Q4	$22.5M	Buy	4,779,708 +1,796	+0%	+$6.63K	0.96%	19
2024 Q3	$17.1M	Buy	+4,777,912	New	+$35.4M	0.86%	25
2023 Q3	–	Sell	-21,370	Closed	-$70.5K	–	139
2023 Q2	$70.5K	Hold	21,370	–	–	0.01%	119
2023 Q1	$60.9K	Sell	21,370 -478,630	-96%	-$4.29M	﹤0.01%	120
2022 Q4	$3.64M	Buy	+500,000	New	+$3.26M	0.24%	58

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nantahala Capital Management's FULC Position: Q2 2026 in Review

Nantahala Capital Management increased its Fulcrum Therapeutics (FULC) stake by 80% in Q2 2026, buying an estimated $14.8M and bringing the position to 5,475,040 shares worth $20M. The position accounts for 0.66% of the portfolio, ranked #42.

Nantahala Capital Management first reported a position in FULC in Q4 2022 and has held it in 11 quarters since. The position peaked at $48.6M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Nantahala Capital Management held 5,475,040 shares of Fulcrum Therapeutics worth $20M as of Q2 2026.
Nantahala Capital Management bought 2,425,000 Fulcrum Therapeutics shares in Q2 2026, an estimated $14.8M.
Fulcrum Therapeutics made up 0.66% of Nantahala Capital Management's portfolio in Q2 2026, its #42 holding.
Nantahala Capital Management first reported a position in Fulcrum Therapeutics in Q4 2022 and has held it in 11 quarters since.
Nantahala Capital Management's Fulcrum Therapeutics position peaked at $48.6M in Q4 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.